Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
ALI HEALTH
00241
5
TENCENT
00700
No Data
No Data
Cybin Advances Clinical Programs in Psychedelic Therapeutics
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones
Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Cybin Completes Enrollment in Phase 2 Study for GAD Treatment
Cybin: Phase 2 GAD Study Enrolled 36 Participants to Evaluate Safety and Efficacy of CYB004 at 12 Weeks After First Dose >CYBN
Cybin to Engage at H.C. Wainwright Investment Conference